Stepan Company outlook amid evolving specialty chemicals demand
Stepan Company operates in the specialty chemicals sector, manufacturing surfactants, polymers, and other performance products for a variety of industries including cleaning, personal care, agriculture, and energy. The company
Enterprise value to revenue forward of Stepan Company – NYSE:SCL
This article provides access to the enterprise value to revenue forward financial data for Stepan Company (NYSE: SCL) on TradingView. It appears to be a financial data page rather than a traditional article, offering various financial tools, market data, and community features related to the stock. The content is primarily a platform navigation and data display, indicating where users can find financial statistics for SCL.
Enterprise value to revenue forward of Stepan Co – FWB:96S
This article provides financial information for Stepan Co (FWB:96S) on TradingView, specifically focusing on its enterprise value to revenue forward. It also lists general information about the company provided on the platform, including market data and links to various TradingView features. The content indicates that the market for Stepan Co (FWB:96S) was closed at the time of publication, with no trades recorded.
Price to earnings forward of Stepan Company – NYSE:SCL
This page provides the "Price to earnings forward" value for Stepan Company (NYSE: SCL). The article indicates the market was closed and no trades were made at the time of viewing. It appears to be a financial data snippet from TradingView.
Stepan (SCL) Joins Russell 2000 Dynamic Index Is Its Small-Cap Profile Quietly Shifting?
Stepan Company (SCL) has been added to the Russell 2000 Dynamic Index, which is expected to increase its visibility and attract more institutional attention. While index inclusion improves liquidity, the company still faces challenges with margin pressure, negative free cash flow, and recent losses, with operational execution being the key to restoring profitability. Analysts project significant revenue and earnings growth by 2029, suggesting a potential 35% upside to its current price.
Stepan Co Financial Disclosures & Filings
This page provides access to Stepan Co's financial disclosures and regulatory filings, including quarterly and annual earnings reports, investor presentations, and key corporate event transcripts. It summarizes performance highlights such as EBITDA growth, strategic initiatives like Project Catalyst, and leadership changes, offering insights for investment decisions. The documents span from Q1 FY22 to Q1 FY2026.
Enterprise value to EBIT forward of Stepan Company – NYSE:SCL
This page from TradingView provides financial information for Stepan Company (NYSE: SCL), specifically focusing on its Enterprise Value to EBIT forward metric. The data is presented within the context of market performance for the company.
Stepan (SCL) Joins Russell 2000 Dynamic Index Is Its Small-Cap Profile Quietly Shifting?
Stepan Company (SCL) has been added to the Russell 2000 Dynamic Index, which is expected to increase its visibility and liquidity among institutional investors. While this inclusion is significant, the company's immediate focus remains on improving profitability, managing raw material and pricing pressures, and scaling new capacity. Forecasts suggest Stepan could reach $2.8 billion in revenue and $137.8 million in earnings by 2029, with a fair value indicating a 35% upside.
Price to sales forward of Stepan Co – DUS:96S
The article provides a financial overview of Stepan Co (DUS:96S) on the Dusseldorf Stock Exchange, focusing on its "Price to sales forward" metric. It indicates that the market is closed with no trades. The content primarily lists navigation and internal links related to TradingView's platform, rather than detailed financial analysis.
Stepan (SCL) Could Be 27% Undervalued On Russell 2000 Index Inclusion
Stepan (SCL) has been added to the Russell 2000 Dynamic Index, which could lead to portfolio adjustments by institutional investors and increased attention on its fundamentals. Despite recent short-term share price growth, a three-year total shareholder return decline suggests a mixed performance history. The article suggests Stepan could be 27% undervalued, with a fair value of $75 due to future profit recovery and margin improvement, particularly with the expected full contribution from its new Pasadena, Texas site in the second half of 2025.
Stepan Company(NYSE: SCL) added to Russell 2000 Dynamic Index
Stepan Company (NYSE: SCL) has been added to the Russell 2000 Dynamic Index. This inclusion highlights the company's position in the market as a producer of intermediate chemicals for various applications including surfactants, polymers, and specialty products. The news was published on June 28, 2026, according to the article.
SCL Forecast — Price Target — Prediction for 2027
This article provides a forecast for Stepan Company (SCL) stock, including a 1-year price target of $75.00 based on one analyst's opinion. It covers current stock performance, historical highs and lows, volatility, market capitalization, and details on earnings, revenue, and dividends. The article also provides information regarding the company's financial statements and recommends doing thorough research before investing.
Stepan Co Actuals & Estimates (NYSE:SCL)
This article provides an overview of Stepan Company (NYSE: SCL) stock, including its current price, historical performance, analyst forecasts, and financial data. It details recent earnings, revenue, dividends, and other key financial metrics, along with FAQs about the company's stock volatility and market capitalization.
The STEPANOL WA-1003 from Stepan Company - liquid surfactant workhorse for daily cleaning
This article introduces STEPANOL WA-1003, a high-activity anionic liquid surfactant produced by Stepan Company, widely used as a base for household and industrial cleaners. It highlights its versatility, strong foaming, and wetting properties, along with its predictable viscosity for easy handling in manufacturing. The article also touches on Stepan Company's broader surfactant portfolio, regulatory compliance, and market position, emphasizing the product's role in underpinning everyday cleaning products.
Stepan Company Stock - Thursday chart and technical snapshot on SCL
This article provides a technical snapshot of Stepan Company (SCL) stock, trading on the NYSE. With no new corporate headlines, the focus is on the stock's chart picture, recent volatility, and key technical reference points, noting its trading in the mid-$50 range below earlier highs. The company generates revenue from specialty and intermediate chemicals, including surfactants and polymers.
Stepan Co (SCL) Institutional Confidence
Stepan Co (SCL) currently holds an institutional shareholding score of 10.00, placing it first in the Chemicals industry. The institutional shareholding proportion is 97.83%, showing a significant quarter-over-quarter increase of 12.78%. The largest institutional shareholder is Bill Nygren (OAKMX), holding 156.97K shares, which constitutes 0.74% of the shares outstanding.
Stepan (SCL) Stock Price, News & Analysis $SCL
Stepan (SCL) stock closed at $53.77 and is currently trading at $52.72 in extended hours. The company, a global manufacturer of specialty and intermediate chemicals, has a "Sell" consensus rating from analysts, with projected earnings growth of 66.81% for the coming year. Stepan has a strong dividend yield of 2.93% and has been increasing its dividend for 57 years.
Stepan Company Stock - Analyst and consensus snapshot on SCL
This article provides an analyst and consensus snapshot on Stepan Company (SCL), a specialty chemicals maker. It discusses how the market views SCL's earnings prospects and valuation, highlighting analyst estimates on revenue, earnings per share, and margins. The report also details the company's revenue streams, dividend policy, and stock trading information.
Stepan Co (SCL) Earnings Forecast: Future EPS & Revenue Growth Estimates
Stepan Co (SCL) has an earnings forecast score of 8.00 within the Chemicals industry, with analysts setting an average price target of $85.00. Based on one analyst's rating, there is a "Buy" trend for the stock, indicating a positive outlook. The company's expected revenue for the next quarter is $635.85 million, and its EPS for the previous quarter was $0.22, with an expectation of $0.65 for the upcoming quarter.
Stepan Company Stock (US8585861003): valuation in focus after recent pullback
Stepan Company shares have pulled back from recent highs, prompting investors to re-evaluate its valuation. The specialty chemicals producer's business model, balance sheet strength, and dividend policy are key factors in assessing its current stock price amidst cyclical pressures and growth opportunities. Investors are weighing the company's fundamentals against macro uncertainties and sector-specific risks.
US Detergent Acid Market in Crisis — LABSA Rises 4.78% as Small Buyers Locked Out of Collapsed Supply Chain
US Linear Alkylbenzene Sulfonic Acid (LABSA) prices surged 4.78% due to a confluence of factors including a 6.1% increase in LAB feedstock prices, Stepan Company's price hike, and Sasol's extended force majeure. This acute supply shortage has locked out small and medium-sized companies from sourcing LABSA. Geopolitical tensions in the Middle East exacerbated the situation, driving up feedstock costs and logistics.
Precision Trading with Stepan Company (SCL) Risk Zones
This article analyzes Stepan Company (SCL) using AI models, offering precision trading strategies for different risk profiles. It identifies a strong near-term sentiment with a neutral mid and long-term outlook, highlighting an exceptional 47.9:1 risk-reward setup targeting a 14.2% gain. The piece provides specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies.
Precision Trading with Stepan Company (SCL) Risk Zones
This article analyzes Stepan Company (SCL) using AI models to provide trading strategies. It highlights a strong near-term sentiment with a neutral mid and long-term outlook, identifying an exceptional risk-reward setup. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are presented with specific entry, target, and stop-loss zones for various risk profiles.
SCL - Stepan Co Stock Price and Quote
This article provides comprehensive financial data for Stepan Co (SCL), including its stock performance, key financial metrics, analyst ratings, and recent news. It highlights the company's current stock price, dividend information, and details on insider transactions, alongside a timeline of earnings reports and strategic announcements.
SCL News | STEPAN CO (NYSE:SCL)
This article provides news and analysis for Stepan Co. (NYSE:SCL), including its current stock price and recent earnings reports. The latest news indicates a 16% plummet after Q4 earnings missed expectations, following mixed Q3 and Q2 2025 results.
Stepan (NYSE: SCL) VP gets new equity grants and fixes option price error
Richard Finn, VP and General Manager of Polymers at Stepan (NYSE: SCL), received new equity compensation, including a stock appreciation right for 7,155 shares, 2,497 performance shares, and 4,994 restricted stock units. An amended Form 4 corrected an administrative error, changing the stock appreciation right's conversion price from $17.47 to $50.06. Following these grants, Finn directly holds 241,395.915 shares of Stepan common stock, in addition to indirect holdings.
STEPAN CO (SCL) director receives 2,566-share stock grant in Form 4 filing
STEPAN CO director Jan Stern Reed was granted 2,566 shares of Common Stock on May 8, 2026, at a value of $52.61 per share. This equity award is classified as a grant rather than an open-market purchase. Following this transaction, Reed directly holds 16,477 shares of STEPAN CO Common Stock, and the filing indicates no insider share sales.
Global Alpha Olefin Sulfonate Market Report 2026-2030 Featuring Strategic Analysis of Stepan Co., Clariant, Nouryon, Kao, Syensqo and More
The global Alpha Olefin Sulfonate (AOS) market is projected to grow from $722.3 million in 2025 to $942.6 million by 2030, driven by increased demand in industrial and institutional cleaning applications and the expansion of consumer goods with improved formulations. Liquid and paste AOS forms are expected to show the highest CAGR due to their solubility and efficiency. North America is a key region, with companies like Stepan Company, Clariant AG, and Kao Corporation leading market innovation.
Stepan (NYSE: SCL) VP reports RSU vesting and 50-share tax withholding
Stepan Company's VP and GM Surfactants-INT, Robin Joseph Weitkamp, reported the vesting of 90 Restricted Stock Units (RSUs) on May 11, 2026. To cover tax obligations, 50 shares of common stock, valued at $52.58 each, were withheld. After these transactions, Weitkamp directly holds 40 shares and indirectly holds 96.9 shares through the ESOP II Trust.
Global Alpha Olefin Sulfonate Market Report 2026-2030
The global alpha olefin sulfonate (AOS) market, valued at $722.3 million in 2025, is projected to reach $942.6 million by 2030, growing at a CAGR of 5.47%. This growth is primarily driven by expanding industrial and institutional cleaning applications and the increasing demand for high-efficiency liquid and concentrated cleaning products. Key players in the market include Stepan Co., Clariant, Nouryon, Kao, and Syensqo.
Global Alpha Olefin Sulfonate Market Report 2026-2030 Featuring Strategic Analysis of Stepan Co., Clariant, Nouryon, Kao, Syensqo and More
The Alpha Olefin Sulfonate (AOS) market is projected to grow from USD 722.3 million in 2025 to USD 942.6 million by 2030, exhibiting a CAGR of 5.47%. This growth is primarily driven by the increasing demand for effective cleaning solutions in industrial and institutional settings, as well as the rising preference for sulfate-free cleaning systems. Key players in this market include Stepan Company, Clariant AG, Nouryon, and Kao Corporation, who are adapting to industry trends such as the shift towards renewable and bio-based surfactants.
Stepan (NYSE: SCL) CFO gets equity grants, fixes SAR exercise price
Stepan Co.'s CFO, Ruben Dario Velasquez, received several equity-based awards, including Stock Appreciation Rights (SARs), performance shares, and restricted stock units. The company filed an amended Form 4 to correct an administrative error in the SAR conversion/exercise price, adjusting it from $17.47 to $50.06. These awards are part of his compensation, aligning his incentives with the company's long-term performance.
Stepan (SCL) CEO Rojo receives major equity grants as SAR price corrected
Stepan (SCL) CEO Luis Rojo received significant equity compensation, including stock appreciation rights, performance shares, restricted stock units, and common stock. An amended Form 4/A was filed to correct an administrative error regarding the conversion price of stock appreciation rights, changing it from $17.47 to $50.06. This filing details the specific grants, vesting schedules, and the correction made, but reports no stock sales.
Stepan (NYSE: SCL) VP GC granted equity awards, corrects SAR exercise price
Stepan Company's VP, General Counsel, and Secretary, Shawn G. Lisle, received new equity compensation awards including stock appreciation rights, performance shares, and restricted stock units. An amendment (Form 4/A) was filed to correct an administrative error in the previously reported exercise price for the stock appreciation rights, changing it from $17.47 to $50.06. All other terms of the awards remain unchanged, indicating these are grants rather than open-market transactions.
Stepan Co (NYSE: SCL) VP Sean Moriarty granted RSUs, performance shares and SARs
Stepan Co. VP Sean Moriarty received various equity compensation awards, including 4,495 restricted stock units, 2,247 performance shares, and 6,440 stock appreciation rights. An amended Form 4/A was filed to correct the SAR exercise price from $17.47 to $50.06, with all other terms remaining unchanged. These awards are part of his routine stock-based compensation and vest over several years based on specific conditions.
Stepan (SCL) VP & CHRO receives stock awards and corrects SAR price in Form 4/A
Stepan Co's VP & CHRO, Andrea Jean Barry, received equity-based compensation including stock appreciation rights, performance shares, and restricted stock units. An amended Form 4/A was filed to correct an administrative error regarding the conversion price of the stock appreciation rights from $17.47 to the accurate price of $50.06. All other terms and conditions of the awards remain unchanged.
How Stepan’s Swing to Q1 Loss With Steady Dividend At Stepan (SCL) Has Changed Its Investment Story
Stepan Company (SCL) reported a swing to a net loss of US$41.41 million in Q1 2026, despite a slight increase in sales to US$604.51 million. Despite this loss, the company affirmed its quarterly dividend of US$0.395 per share. This financial shift raises questions about margin resilience and cash generation for investors, who will closely monitor the sustainability of the dividend and the company's efforts to return to profitability.
STEPAN CO 1Q 2026: Revenue $604.5M, EPS $(1.81) — 10-Q Summary
STEPAN CO (SCL) reported first-quarter 2026 results with a significant increase in consolidated net sales to $604.5M, up 2% year-over-year. However, the company posted a net loss of $(41.4)M, or diluted EPS of $(1.81), primarily due to a substantial $51.2M after-tax restructuring charge related to Project Catalyst. Despite a volume decline, revenue growth was driven by surfactants and favorable foreign exchange rates, alongside strategic operational restructuring and capacity shifts.
A Look At Stepan (SCL) Valuation After Profitability Reverses In Latest Quarterly Results
Stepan (SCL) reported a net loss of US$41.41 million in Q1 2026, reversing profitability from the previous year, despite sales of US$604.51 million. The stock has seen mixed performance, with short-term declines around the earnings release but a 7.70% year-to-date gain. Analysts believe Stepan is currently undervalued with a fair value of $75, anticipating positive impacts from a new Pasadena, Texas site reaching full contribution by H2 2025.
Stepan (NYSE: SCL) EVP exercises RSUs with shares withheld for taxes
Stepan Company's EVP, Robert Joseph Haire, engaged in routine equity compensation activity, settling 550 restricted stock units (RSUs) into common shares. To cover tax liabilities, 162 common shares were withheld, a non-market disposition. Following these transactions, Haire directly holds approximately 3,959.765 shares of Stepan common stock.
A Look At Stepan (SCL) Valuation After Profitability Reverses In Latest Quarterly Results
Stepan (SCL) reported a net loss of US$41.41 million in Q1 2026, reversing its previous year's net income, despite sales of US$604.51 million. The stock has seen declines recently but a 7.70% year-to-date gain, with analysts pegging its fair value at US$75, suggesting it is undervalued at its current price of US$50.79. Future growth is anticipated from a new Pasadena, Texas site and a mixed outlook of concern and optimism.
Stepan Co (SCL) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100
Stepan Co (SCL) stock rose 3.1% to $51.59, and is considered significantly undervalued with a GF Value of $79.92, offering a 35.4% upside potential. The company has a GF Score of 77/100, indicating an above-average profile, particularly in profitability and momentum, despite lower scores in growth and valuation. There have been no insider transactions in the last three months, and its current forward P/E of 18.9x is below its 5-year median, further suggesting undervaluation.
Stepan (NYSE:SCL) Stock Forecast & Analyst Predictions
Stepan (NYSE:SCL) is forecast to see significant earnings growth of 174.6% and revenue growth of 4.8% per annum. While analysts have kept the fair value estimate steady at $75.00, consensus EPS estimates have seen some reductions, and the company has announced recent dividends and faced some goodwill impairment charges.
Stepan Stockholders Back Directors, Pay and Auditor Choices
At its Annual Meeting on April 28, 2026, Stepan Company shareholders re-elected directors Joaquin Delgado, Corning F. Painter, and F. Quinn Stepan, Jr., ensuring leadership continuity. Additionally, stockholders approved executive compensation and ratified Deloitte & Touche LLP as the independent auditor for 2026, affirming strong corporate governance and oversight. TipRanks' AI Analyst, Spark, rates SCL as Neutral, citing improving financial stability but tempered by weak profitability and near-term margin pressure.
Shareholders at Stepan (NYSE: SCL) back directors, executive pay and 2026 auditor
Stepan Company (NYSE: SCL) shareholders approved all proposals at their April 28, 2026, annual meeting, including the election of three directors to terms expiring in 2029. Stockholders also gave advisory approval to executive compensation and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026. The votes demonstrate strong shareholder support for the company's governance and management.
[SCHEDULE 13G] STEPAN CO Passive Investment Disclosure (>5%)
Vanguard Portfolio Management has reported a passive investment in Stepan Co (SCL) through a Schedule 13G filing, disclosing beneficial ownership of 1,372,514 shares, which equates to 6.04% of the company's common stock. This filing indicates that Vanguard holds significant dispositive power over these shares, but limited sole voting power, characteristic of pooled fund structures and passive investment strategies. The disclosure confirms that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing company control.
Stepan’s Swing to Quarterly Loss and Dividend Increase Might Change The Case For Investing In SCL
Stepan Company reported a swing to a net loss of US$41.41 million in Q1 2026, despite a slight increase in sales, challenging its investment narrative built on margin improvement. However, the company affirmed its quarterly dividend, extending a 58-year streak of increases, emphasizing management's commitment to shareholder payouts. This situation highlights the importance of clarifying the drivers behind the weaker profitability and the company's ability to maintain cash generation.
Stepan Company (NYSE:SCL) Q1 2026 Earnings Call Transcript
Stepan Company reported its Q1 2026 earnings, beating expectations with an EPS of $0.45 against an anticipated $0.385. The company highlighted net sales growth in a challenging macroeconomic environment, driven by double-digit volume increases in Crop Productivity, Oilfield, Industrial Cleaning, and Tier 2/3 customer segments. Despite a decrease in adjusted EBITDA due to Surfactant segment challenges, the company is optimistic about future quarters, anticipating recovery from temporary issues and significant savings from Project Catalyst.
Stepan Co (SCL) Q1 2026 Earnings Call Highlights: Record Safety Performance Amidst Challenges By GuruFocus
Stepan Co (SCL) announced record safety performance in Q1 2026, alongside a 4% organic net sales increase. Despite this, adjusted EBITDA declined by 14% due to lower surfactant results and higher interest expenses, leading to a net loss of $41.4 million primarily from restructuring charges. The company is managing challenges like raw material inflation from geopolitical events and competitive pressures in the surfactants business, while focusing on growth in Tier 2 and Tier 3 customer segments and North American polymers.
Stepan Company Plans Quarterly Dividend of $0.40 (NYSE:SCL)
Stepan Company (NYSE:SCL) has declared a quarterly dividend of $0.395 per share, payable on June 15th to shareholders of record on June 1st. This dividend represents an annualized yield of 3.2% and marks the 57th consecutive year the company has raised its dividend. Despite missing revenue estimates, Stepan reported Q1 earnings of $0.45 per share, beating analyst expectations by $0.01.
